FDA approves OTC handheld heart rhythm monitor

The FDA approved over-the-counter (OTC) sales and marketing of the HeartCheck Pen Handheld ECG, a handheld heart rhythm monitor manufactured by CardioComm Solutions.

The HeartCheck Pen takes heart readings in 30 seconds and can store up to 20 ECGs at a time, according to the Toronto-based health IT and ECG developer. After taking a reading, patients can view their heart rate count only when they consult with a physician, who can unlock stored data to display the real-time ECG and heart rate counts for subsequent heart rhythm recordings.

Also approved by the FDA was CardioComm Solutions’ GEMS Home software, which enables patients to upload data from the HeartCheck Pen to their personal computer and transmit it to a provider using CardioComm Solutions’ C4 ECG Management Service software. 

Around the web

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."

Trimed Popup
Trimed Popup